Aravive — Investor Presentation (January 2020)
29 slides from Aravive's investor presentation, Jan 13, 2020
Slide 1: Aravive Corporate Presentation January 2020
Halting Disease Progression in its Tracks © 2019 Aravive, Inc. Aravive Corporate Presentation January 2020 Exhibit 99.1
Slide 2: Important Information: Forward-Looking Statements
Important Information © 2019 Aravive, Inc. Forward-Looking Statements This presentation contains forward-looking statements that may discuss Aravive’s plans, goals, intentions and expectations as to future trends, events, results of operations, financial condition or other matters. Forward- looking
Slide 3: Company Overview
Company Overview The Company Lead Clinical Program (AVB-500) Aravive is a clinical stage company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis NASDAQ-listed company (ARAV) Offices in Houston, TX (hdqtrs.) and Palo Alto, CA $20 mill
Slide 4: Pipeline Focused on GAS6/AXL Signaling in Oncology & Fibrosis
Pipeline Focused on GAS6/AXL Signaling in Oncology & Fibrosis Indication Preclinical Phase 1 Phase 1*Phase 1b Phase 2 Phase 3 AVB-S6-TBD Ovarian Cancer platinum resistant Clear Cell Renal Cancer 3rd Oncology (undisclosed indication) Kidney Fibrosis (IgAN) Chronic Fibrosis (undisclosed indication) AV
Slide 5: AXL Tyrosine Kinase Promotes Invasion, Metastasis, and Resistance
AXL Tyrosine Kinase Promotes Invasion, Metastasis, and Resistance AXL is a member of tyrosine kinases that include Tyro3, AXL, and Mer (TAMs) AXL is activated by a single ligand, growth arrest–specific 6 (GAS6); Mer and Tyro3 can be activated by GAS6 and Protein S 1 Upregulated in many cancers 2, AX
Slide 6: GAS6/AXL Signaling: Decoy Receptor is the Best Approach
GAS6/AXL Signaling: Decoy Receptor is the Best Approach for Potent and Selective Inhibition WT AXL has pM Affinity; AVB-500 AXL Decoy has fM Affinity Selectivity limited by RTK homology Off-target toxicity Multiple resistance mechanisms Many potential competitors Decoy AXL Receptor AXL or GAS6 Antib
Slide 7: Other Drugs Targeting AXL Signaling are Not Selective
Other Drugs Targeting AXL Signaling in Clinical Development are Not Selective Drug (Stage) Company Target Selective for AXL AVB-500 (Ph Ib/II) Aravive GAS6 YES Gilterinib (Market) Astellas AXL NO Cabozantinib (Market) Exelixis AXL NO Sitravatinib (Ph III) Mirati (BeiGene) AXL NO Merestinib (Ph II) L
Slide 8: AVB-500 Inhibits AXL Signaling by Neutralizing GAS6
AVB-500 Inhibits AXL Signaling by Neutralizing GAS6, Sole Ligand for AXL Decoy receptor engineered for very high affinity for GAS6 – ~200 fold greater than native AXL Favorable safety and PK profile GAS6 not needed by normal tissue GLP preclinical studies demonstrate ≥ 30-fold safety margin (relativ
Slide 9: GAS6/AXL Signaling is Critical in Resistant Metastatic Ovarian Cancer
GAS6/AXL Signaling is Critical in Resistant Metastatic Ovarian Cancer Expression in 0% (0/10) of normal ovarian tissue Expression in 73% (219/297) ovarian tumor samples including low grade serous, endometroid and advanced stage tumors1 Preclinical in vitro 1,2,3 Inhibition decreases invasion/migrati
Slide 10: AVB-500: A Novel Lead Clinical Program With Attractive Attributes
AVB-500: A Novel Lead Clinical Program With Attractive Attributes Fast-track designation granted by the FDA for platinum-resistant ovarian cancer; currently in expanded Phase 1b/2 trial with early proof-of-concept data Well-tolerated to date and no anticipated drug-drug interactions facilitate combi
Slide 11: AVB500-OC-002: P1b Study in Platinum-Resistant Ovarian Cancer
AVB500-OC-002: A P1b Study of AVB-500 in Combination with Single Agent Chemotherapy in Platinum-Resistant Ovarian Cancer Key Eligibility Criteria 1-3 prior lines Measurable disease Platinum free interval ≤ 6mo after most recent platinum-containing regimen Adenocarcinoma NOS, high grade endometroid a
Slide 12: Safety data for the first patients: AVB-500 well-tolerated
Safety data for the first 31 patients: AVB-500 (10mg/kg) well-tolerated No serious and unexpected adverse reactions No dose limiting toxicities Infusion reactions managed by premedication regimen 40 patients total have been dosed at 10mg/kg Similar safety profile as that seen with first 31 patients
Slide 13: Exposure-Response Analysis Demonstrated AVB-500 Levels Predict Clinical Benefit
Exposure-Response Analysis Demonstrated AVB-500 Levels at 10mg/kg Dose Predict Clinical Benefit © 2019 Aravive, Inc. Above Minimal Efficacious Exposure Below Minimal Efficacious Exposure Number of Patients (n) 17 14 Complete Response (CR) 1 (6%) 0 Partial Response (PR) 4 (24%) 2 (14%) Overall Respon
Slide 14: Response and CBR in Second and Third Line Better than Historical Control
Response and CBR in Second and Third Line Treatments Better with AVB-500 than Historical Control Cancer Chemotherapy and Pharmacology (2019) 84:33-39 37 European Journal of Obstetrics & Gynecology and Reproductive Biology 166 (2013) 94–98 Prior Lines AVB500-OC-002 Data from Literature (Plat-S/Plat-R
Slide 15: Observations on Patients On Study as of October 2019
Observations on Patients On Study as of October 31 2019 (10mg/kg dose) The patient with CR achieved the minimal efficacious concentration of AVB-500 while on PAC. She had a baseline serum GAS6 level that was typical of the platinum-resistant ovarian cancer population and 2-fold higher than that obse
Slide 16: Best Response by RECISTv1.1 for First 31 Patients
Best Response Determined by Investigator-Assessed RECISTv1.1 for First 31 Patients (10mg/kg): One CR Percent Change in Sum of Target Tumors from Baseline to Best Response Note: 2 pts who were PD at best response (Pac arm) are excluded from the waterfall Pac PLD High exposure patients
Slide 17: Summary of First Patients' Response as of October 2019
Summary of First 31 Patients’ Response as of October 31 2019 CT Scans PAC PLD Partial response Progressed Complete response Stable disease represented by continuous bar * * * * * * * * * * * * * * * * * * High exposure patients Withdrew consent and off study
Slide 18: Comparable Demographics and Baseline Characteristics
Comparable Demographics and Baseline Characteristics Confirming AVB-500 Exposure Drives Anti-Tumor Activity Above Minimal Efficacious Concentration Below Minimal Efficacious Concentration Age, years median (min, max) 71 (52-82) 63.0 (53-80) Prior lines* 1 (%) 6 (35.3%) 2 (14.3%) 2 (%) 8 (47.1%) 6 (4
Slide 19: Next Steps
Next Steps Data confirm strategy to investigate higher doses in the current Phase 1b study to determine if a greater proportion of patients achieve high drug exposure levels PK modeling predict a dose of 20 mg/kg should allow >90% of patients to achieve desired high exposure levels Anticipate 18-24
Slide 20: Platinum-Resistant Ovarian Cancer Phase 2/3
Platinum-Resistant Ovarian Cancer Phase 2/3 P1b Will Determine RP2D Anticipate initiating 2H20 Same population as P1b portion Effect size from P1b (all AVB-500 doses) will drive regulatory strategy, statistical plan, Ns Randomized (2:1), double-blind, placebo- controlled study to compare efficacy an
Slide 21: Rationale for AVB-500 in Kidney Cancer
Rationale for AVB-500 in Kidney Cancer Strong biological rationale for clear cell Renal Cell Cancer1 VHL tumor suppressor gene mutated, causes increase in AXL AXL/GAS6 levels predict prognosis & survival in human1 Strong in vivo activity in preclinical models1,2 single agent combo with TKI 2 Xiao et
Slide 22: Overview of P1b/P2 Clear Cell Renal Cell Carcinoma
Overview of P1b/P2 Clear Cell Renal Cell Carcinoma Histologically confirmed stage IV ccRCC (according to the American Joint Commission on Cancer, seventh edition, classification) and has progressed on/after or was intolerant to front-line treatment ECOG 0-1 Phase 1b safety run-in with AVB-500 in com
Slide 23: Rationale for AVB-500 in Kidney Fibrosis
Rationale for AVB-500 in Kidney Fibrosis GAS6 acts as a mitogen, stimulating mesangial cell proliferation through binding to its cell-surface receptor AXL Mesangial proliferation is a hallmark of IgAN 1 Coppo et al, Kidney Intl (2014) 86:828-36; Reich et al, J Am Soc Nephrol (2007) 3177-83; Nagai K,
Slide 24: Overview of Phase 2A IgAN Study
Overview of Phase 2A IgAN Study Small (N of 12-24) Proof of Concept Study in IgA patients Sites in USA and Ukraine Diagnosis of biopsy-proven IgAN Proteinuria ≥ 1g to 3g/24hr Monitor safety, PK/PD Ensure sGAS6 levels suppressed throughout dosing interval Open-label Monitor proteinuria and other rena
Slide 25: AXL Promotes a Suppressive Myeloid Micro-environment
AXL Promotes a Suppressive Myeloid Micro-environment ISTs Investigating Combinations of AVB-500 + PDL1 inhibitor AXL presence Decreases tumor T cells (killer) infiltration Decreases Tumor antigen presentation Increases suppressive myeloid cells and macrophages AXL loss Increases Tumor antigen expres
Slide 26: Experienced, Methodical, Efficient Development Execution
Experienced, Methodical, Efficient Development Execution Strong Clinical Development Team © 2019 Aravive, Inc. Dev Plan Enabled Bifurcated Strategy- Oncology and Fibrosis 4Q 2017- IND filed 1Q 2018- FIH in NHV initiated 2Q 2018- POM in NHV 3Q 2018- Tolerability in NHV 4Q 2018- P1b in Ovarian Cancer
Slide 27: Financials and Capitalization
Financials and Capitalization NASDAQ: ARAV; Shares Outstanding*: 14.9M basic * As of September 30, 2019 adjusted for net proceeds from recent public offering, closed on December 2, 2019 Cash and cash equivalents*: $70M Cash and cash equivalents expected to enable the company to fund its operating pl
Slide 28: AVB-500 Offers First- and Best-In-Class Opportunity in Oncology and Fibrosis
AVB-500 Offers First- and Best-In-Class Opportunity in Oncology and Fibrosis Uniquely positioned in competitive landscape Robust pipeline addressing significant drivers of mortality in oncology and fibrosis: metastasis and drug resistance © 2019 Aravive, Inc. AVB-500: high affinity decoy protein, a
Slide 29: Thank You
Halting Disease Progression in its Tracks © 2019 Aravive, Inc. Thank You